AstraZeneca had net income of US$ 1.642 billion in the third quarter of this year, which reversed the loss of US$ 1.651 billion in the same period last year. The result beat analysts’ forecast of $629 million.
Profit before tax was $922 million, down from a loss of $2 billion previously. In the third quarter of 2021, results had been affected by adjustments in Alexion’s inventories, following the purchase of this company.
The Anglo-Swedish pharmaceutical company’s total sales were $10.982 billion and product sales were $10.590 billion in the third quarter of 2022. Total sales beat analysts’ forecast of $10.84 billion.
AstraZeneca even raised its guidance for the entire current year. It expects its core earnings per share to advance by about 30%, while the expectation of growth in total revenue has been maintained.
Source: CNN Brasil
Joe Jameson, a technology journalist with over 2 years of experience, writes for top online news websites. Specializing in the field of technology, Joe provides insights into the latest advancements in the industry. Currently, he contributes to covering the world stock market.
